Prostate

Game Changer Vehicle Takes PSA Screening Mobile

Sylvester Comprehensive Cancer Center’s Game Changer vehicles are offering PSA screening for prostate cancer.

Prostate

FDA Grants Breakthrough Designation for Early-Stage Prostate Cancer Detection Blood Test

The FDA has granted Breakthrough Device Designation for Datar Cancer Genetics’ TriNetra-Prostate blood test to detect early-stage prostate cancer.

Prostate

Prostate Cancer Urine Test Identifies Good Prognosis Patients

A prostate cancer urine test can identify men at intermediate risk who can safely avoid immediate treatment and benefit from active surveillance instead.

Novel Blood Test Can Cut Prostate Cancer Biopsies by a Third

Aug 13, 2021 | Prostate

Researchers at Karolinska Institutet in Sweden recently reported that magnetic resonance imaging...

JAMA Study: Covid-19 Had Significant Consequences for Cancer Screening

May 4, 2021 | Prostate

Because of the covid-19 pandemic, nearly 10 million patients weren’t screened for cancer, including breast, colorectal, and prostate.

New Line of Urology Testing to Screen for Prostate Cancer and Renal Cancer Hereditary Genetics

Mar 15, 2021 | Cytology, Molecular Diagnostics, Prostate

Medical Diagnostic Laboratories’ approach blends DNA-based molecular testing with traditional pathology and cytology tests to aid in diagnosing or screening for urologic conditions.

Improved Prostate Cancer Diagnosis with AI-powered Workflows

Mar 11, 2021 | Analytical Software Systems, Company News, Prostate

Proscia and Ibex Medical Analytics are collaborating to deliver a unified software solution that powers AI-enabled workflows for prostate cancer diagnosis.

Learning from Prostate Cancer-Detecting Dogs to Improve Diagnostics

Mar 5, 2021 | Prostate

New research demonstrates the ability of dogs to detect aggressive prostate cancer from urine samples and suggests that an artificial neural network could learn from this olfactory ability, with an eye toward replicating it in novel detection tools.

Propella Therapeutics, National Cancer Institute to Develop Treatment for Metastatic Prostate Cancer

Mar 1, 2021 | Prostate

Under this new partnership, Propella and NCI will conduct a multi-center clinical trial to evaluate abiraterone decanoate as a new therapy for metastatic prostate cancer.

Study: New Prostate Cancer Test Could Avoid Unnecessary Biopsies

Feb 26, 2021 | Prostate, Urinalysis & Toxicology

A urine test could have avoided one-third of unnecessary prostate cancer biopsies while failing to detect only a small number of cancers, according to a validation study.

Study Validates Ability of Myriad Genetics’ Prolaris Test to Guide Treatment for Prostate Cancer

Feb 16, 2021 | Prostate

The Prolaris test can more accurately predict the aggressiveness of prostate cancer allowing for more precise treatment and avoidance of more intense therapies with a patient’s parallel morbidities.

Decipher Prostate Test Clinically Validated as Predictor of Overall Survival

Feb 12, 2021 | Prostate

The study validated the Decipher RP test as an independent predictor of distant metastases, prostate cancer-specific mortality, and overall survival.

Veracyte to Acquire Decipher Biosciences

Feb 5, 2021 | Company News, Prostate, Sequencing Systems, Unknown Origin & Other Cancer Types

Decipher’s comprehensive portfolio of tests in urologic cancers leverage whole transcriptome analysis and proprietary machine learning algorithms to improve patient decision-making.

Research Detects HULLK in Prostate Cancer

Nov 13, 2020 | Prostate, Research, Urinalysis & Toxicology

The study data provides a potential new approach to early detection of prostate cancer and an alternative to invasive biopsies.

Medicare Expands Coverage for BRACAnalysis CDx in Prostate Cancer

Aug 13, 2020 | Molecular Diagnostics, Prostate

Medicare expanded coverage for BRACAnalysis CDx for men with prostate cancer who are eligible or may become eligible for treatment with Lynparza (olaparib).

miR Scientific Noninvasive Prostate Cancer Test Validation Published

Aug 11, 2020 | Prostate

miR Scientific’s urine-based, noninvasive cancer test can detect molecular evidence of prostate cancer with sensitivity of 94% and specificity of 92%.